369 related articles for article (PubMed ID: 20055743)
1. The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus.
van de Sande WW; Tavakol M; van Vianen W; Bakker-Woudenberg IA
Med Mycol; 2010 Feb; 48(1):48-55. PubMed ID: 20055743
[TBL] [Abstract][Full Text] [Related]
2. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms.
Mowat E; Lang S; Williams C; McCulloch E; Jones B; Ramage G
J Antimicrob Chemother; 2008 Dec; 62(6):1281-4. PubMed ID: 18819968
[TBL] [Abstract][Full Text] [Related]
3. Comparison between Aspergillus fumigatus conidia and hyphae susceptibilities to amphotericin B, itraconazole, and voriconazole by use of the mold rapid susceptibility assay.
Wetter TJ; Hazen KC; Cutler JE
Med Mycol; 2005 Sep; 43(6):525-32. PubMed ID: 16323310
[TBL] [Abstract][Full Text] [Related]
4. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
5. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
6. The evaluation of in vitro pharmacodynamic properties of amphotericin B, voriconazole and caspofungin against A. fumigatus isolates by the conventional and colorimetric time-kill assays.
Kiraz N; Oz Y; Dag I
Med Mycol; 2011 Aug; 49(6):594-601. PubMed ID: 21299374
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.
Krishnan S; Manavathu EK; Chandrasekar PH
J Antimicrob Chemother; 2005 Jun; 55(6):914-20. PubMed ID: 15824093
[TBL] [Abstract][Full Text] [Related]
11. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.
Chandrasekar PH; Cutright JL; Manavathu EK
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):211-4. PubMed ID: 11777662
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
Araujo R; Pina-Vaz C; Rodrigues AG
Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
[TBL] [Abstract][Full Text] [Related]
13. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
Beernaert LA; Pasmans F; Van Waeyenberghe L; Dorrestein GM; Verstappen F; Vercammen F; Haesebrouck F; Martel A
Antimicrob Agents Chemother; 2009 May; 53(5):2199-201. PubMed ID: 19258265
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
15. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.
Lass-Flörl C; Nagl M; Speth C; Ulmer H; Dierich MP; Würzner R
Antimicrob Agents Chemother; 2001 Jan; 45(1):124-8. PubMed ID: 11120954
[TBL] [Abstract][Full Text] [Related]
16. In vitro testing of Aspergillus fumigatus clinical isolates for susceptibility to voriconazole, amphotericin B and itraconazole: comparison of sensititre versus NCCLS M38-A using two different inocula.
Drago M; Scaltrito MM; Cariani L; Morace G
J Chemother; 2004 Oct; 16(5):474-8. PubMed ID: 15565915
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
[TBL] [Abstract][Full Text] [Related]
18. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
Arendrup MC; Perkhofer S; Howard SJ; Garcia-Effron G; Vishukumar A; Perlin D; Lass-Flörl C
Antimicrob Agents Chemother; 2008 Oct; 52(10):3504-11. PubMed ID: 18644959
[TBL] [Abstract][Full Text] [Related]
19. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus.
Choi JH; Brummer E; Stevens DA
Microbes Infect; 2004 Apr; 6(4):383-9. PubMed ID: 15050966
[TBL] [Abstract][Full Text] [Related]
20. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.
Meletiadis J; Antachopoulos C; Stergiopoulou T; Pournaras S; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3329-37. PubMed ID: 17576838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
